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Abstract
Purpose The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI) 
study contains an unparalleled wealth of comprehensive data that allows for testing hypotheses about (1) variations in 
incidence within and between countries, including by urbanicity and minority ethnic groups; and (2) the role of multiple 
environmental and genetic risk factors, and their interactions, in the development of psychotic disorders.
Methods Between 2010 and 2015, we identified 2774 incident cases of psychotic disorders during 12.9 million person-years 
at risk, across 17 sites in 6 countries (UK, The Netherlands, France, Spain, Italy, and Brazil). Of the 2774 incident cases, 
1130 cases were assessed in detail and form the case sample for case–control analyses. Across all sites, 1497 controls were 
recruited and assessed. We collected data on an extensive range of exposures and outcomes, including demographic, clinical 
(e.g. premorbid adjustment), social (e.g. childhood and adult adversity, cannabis use, migration, discrimination), cognitive 
(e.g. IQ, facial affect processing, attributional biases), and biological (DNA via blood sample/cheek swab). We describe the 
methodology of the study and some descriptive results, including representativeness of the cohort.
Conclusions This resource constitutes the largest and most extensive incidence and case–control study of psychosis ever 
conducted.
Keywords Case–control · Environment–environment interactions · EU-GEI · First-episode psychosis · Gene–environment 
interactions · Incidence
Introduction
The lifetime prevalence of psychotic disorders is around 3% 
[1]. The associated individual, familial, social, and economic 
costs are vast. Psychotic disorders cause considerable dis-
tress to sufferers and their families and often lead to marked 
social dysfunction and exclusion. The economic costs are 
huge: in Europe, an estimated €94 billion per year [2], of 
which over half is due to the indirect costs of unemployment, 
lost productivity, and informal care [3]. The World Health 
Organisation estimated that in Western countries, the treat-
ment and care of patients with a psychotic disorder range 
from 1.6 to 2.6% of total healthcare expenditures [4]. Fur-
ther, individuals with a psychotic disorder are far more likely 
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to have a physical health problem [5] and to die younger, by 
as much as 20 years on average, compared with the general 
population [6].
Our knowledge of the distribution and determinants of 
psychotic disorders has increased in recent years. The inci-
dence varies by area (e.g. higher in some urban versus rural 
areas) [7, 8] and social group (e.g. higher in some minority 
ethnic groups) [9, 10] and, in addition to well-established 
genetic and neurodevelopmental risk factors [11, 12], there 
is now substantial evidence implicating several environmen-
tal risk factors [13], such as childhood adversity [14, 15] and 
cannabis use [16]. Pooled relative risks for these risk fac-
tors range between two and four, and population attributable 
risk fractions range between 20 and 35% [17, 18]. Further, 
there is accumulating evidence that these myriad risk factors 
interact in complex ways to increase risk of psychosis via 
effects on the dopaminergic system, dysregulation of which 
may be the biological process that underpins the formation 
of psychotic experiences.
However, there remain many gaps, inconsistencies, and 
unanswered questions, and recent work hints at different 
patterns of risk in different settings. For example, recent 
evidence has failed to show a universal association between 
city living and psychosis [19, 20]. To further add to this 
conundrum, Colodro-Conde et al. [21] found that the high 
prevalence of psychosis in some urban areas may be due 
to gene–environment selection, such that individuals with 
higher genetic loading for psychosis live in more densely 
populated areas. More generally, this points to a major 
limitation to our current knowledge of psychotic disorders: 
we know that environments affect onset and outcomes, but 
research so far has been conducted—with some important 
exceptions—in a remarkably small number of settings (i.e. 
select centres in the US, UK, and Australasia). Combined, 
these points emphasise the need for research in more diverse 
contexts to examine more nuanced hypotheses on the com-
plex interplay between biology and environments in the aeti-
ology of psychotic disorders.
Our knowledge of psychotic disorders is limited, in part, 
because of heterogeneity in methods, which limits our abil-
ity to compare findings across populations [22]. For exam-
ple, differences in study design (i.e. case-register, versus 
cohort-based designs, versus first-contact studies), the age 
structures of populations at risk, case-identification proce-
dures, diagnostic criteria, definitions and measurement of 
environmental factors, and analytic strategies have made 
cross-country comparisons difficult and likely obscured 
important clues to aetiology [23]. The only large-scale 
international comparative studies conducted to date are the 
World Health Organisation’s multi-country projects of the 
1970s and 1980s, which compared the incidence and clinical 
and social characteristics of treated cases of psychoses from 
twelve diverse settings in ten countries using a standardised 
procedure for case identification and data collection [24]. 
However, since this landmark programme, there have been 
far-reaching economic and social changes (e.g. migration 
patterns, cannabis availability and use, and distribution of 
social risks) with conceivable impacts on the social epide-
miology and aetiology of the psychoses. Moreover, studies 
of environment–gene interactions in psychotic disorders are 
rare and have typically involved small samples, with limited 
phenotyping and limited assessment of environmental fac-
tors [21, 25, 26].
The EU-GEI programme was established to address 
these gaps and limitations [27]. EU-GEI is a multi-national 
research collaboration that was funded for 5 years (1 May 
2010–30 April 2015). It consisted of 11 Work Packages (see 
Supplementary Table S1). This paper profiles the incidence 
and case–control programme of work (Work Package 2), 
which comprises the largest multi-site study of psychotic 
disorders ever conducted. In this paper, we describe the 
objectives and main aspects of the study.
Objectives
The overall goal of the present work package was to investi-
gate the role of multiple environmental and genetic risk fac-
tors, and their interactions, in the development of psychotic 
disorders. Specifically, our aims were (1) to investigate the 
impact of hypothesized environmental exposures, measured 
at individual and area levels, on (a) risk of psychotic dis-
orders, and (b) high rates of disorder in urban areas and 
in migrant and minority ethnic groups; and (2) to examine 
hypothesized (a) gene × environment interactions (GxE), 
and (b) environment × environment interactions (ExE) 
across the life course.
Methods
Study design
The data resource comprises a multi-site population-based 
incidence and case–control sample of cases with a first epi-
sode of psychosis [International Classification of Diseases 
(ICD)-10 diagnoses F20–29 and F30–33] and controls drawn 
from tightly defined catchment areas in 17 sites in 6 coun-
tries (England, The Netherlands, France, Spain, Italy, and 
Brazil; see Fig. 1). The sites were purposefully selected to 
include a mix of urban and rural areas, with varying propor-
tions from minority ethnic groups (see Table 1). 
Sample
Recruitment and data collection were conducted over a 
5-year period between 2010 and 2015 (Table 1). We also 
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added data from the Veneto region, Italy, collected as part 
of an earlier study [the Psychosis Incident Cohort Out-
come Study (PICOS); 2005–2007], but with sufficiently 
similar methods to be pooled with that collected for this 
study. The incidence sample comprised 2774 individu-
als with a first episode of psychosis. Of these, 1519 were 
approached, and 1130 were consented and assessed (41% 
of the total incidence sample). Reasons for non-partici-
pation among cases who were approached were refusal 
to participate, language barriers, and exclusion after con-
senting as they did not meet the age inclusion criteria. In 
addition, 1497 controls were recruited and assessed.
Statistical power
Our sample of 1130 cases and 1497 controls has high statis-
tical power to test our primary study hypotheses, even after 
accounting for missing data and for the current necessity 
of restricting genetic analyses to individuals of non-Afri-
can ancestry. For example, in a restricted sample of cases 
1031 and 1438 controls, we have greater than 80% power to 
detect an interaction odds ratio of 1.2 at p ≤ 0.05, assuming 
an odds ratio of 2.0 for an environmental exposure and of 
1.2 for each unit increase in polygenic score [assuming N 
(0.1) distribution].
Fig. 1  Map of EU-GEI settings for the incidence and case–control Work Package
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Case ascertainment and recruitment
All cases presenting to one of the 17 participating centres in 
6 countries with a suspected first episode of psychosis were 
potentially eligible for inclusion in the study. The inclusion 
criteria for cases were (a) presence of at least one positive 
psychotic symptom for at least 1 day duration or two nega-
tive psychotic symptoms (for at least 6 months duration) 
within the timeframe of the study; (b) aged between 18 and 
64 years (inclusive); and (c) resident within a clearly defined 
catchment area at the time of their first presentation. Resi-
dence was defined as a minimum of a one night stay at a resi-
dential address within the catchment areas. Exclusion crite-
ria were (a) previous contact with specialist mental health 
services for psychotic symptoms outside of the study period 
at each site; (b) evidence of psychotic symptoms precipitated 
by an organic cause (ICD-10: F09); (c) transient psychotic 
symptoms resulting from acute intoxication (F1X.5); (d) 
severe learning disabilities, defined by an IQ less than 50 or 
diagnosis of intellectual disability (F70–F79); and, for the 
case–control part only, (e) insufficient fluency of the primary 
language at each site to complete assessments.
Case identification procedures involved teams of 
researchers regularly screening both general adult and spe-
cialist mental health services (both in- and out-patients). The 
screening process involved researchers regularly liaising 
with clinical staff and checking clinical records to identity 
potential cases. The researchers only included those indi-
viduals who they could be sure met the criteria based on the 
symptoms reported in the clinical notes. Potential cases were 
then approached when considered appropriate by clinical 
staff and informed consent sought.
Control recruitment
Inclusion criteria for controls were (a) aged between 18 
and 64 years; (b) resident within a clearly defined catch-
ment area at the time of consent into the study; (c) sufficient 
command of the primary language at each site to complete 
assessments; and (d) no current or past psychotic disorder. 
Table 1  Recruitment period and duration, and number of incidence and consented cases and controls, per site
a Urban site of comparison











 Southeast  Londona 262b 201 n/a 230 01/05/2010 01/05/2013 36
 Cambridgeshire 266 45 16.9 106 01/10/2010 30/09/2013 36
The Netherlands
 Amsterdama 292 96 32.9 101 01/10/2010 01/10/2013 36
 Gouda and Voorhout 167 100 59.9 109 01/12/2010 01/12/2013 36
Spain
 Madrida 89 39 43.8 38 23/02/2011 31/12/2012 22
 Barcelonaa 108 31 28.7 37 20/12/2010 31/12/2012 25
 Valenciaa 58 49 84.5 32 22/12/2010 31/12/2012 24
 Oviedo 82 39 47.6 39 13/12/2010 31/12/2012 25
 Santiago 36 28 77.8 38 13/12/2010 31/12/2012 25
 Cuenca 27 18 66.7 38 08/02/2011 31/12/2012 23
France
 Parisa 120 36 30.0 0 01/06/2012 01/06/2014 24
 Val-de-Marnea 212 54 25.5 100 01/06/2010 01/06/2014 48
 Puy-de-Dôme 42 15 35.7 47 01/09/2010 31/08/2012 24
Italy
 Bolognaa 165 70 42.4 65 01/01/2011 31/12/2014 48
 Veneto 104 59 56.7 115 02/01/2005 31/12/2007 36
 Palermoa 179 58 32.4 100 02/10/2010 31/05/2014 44
Brazil
 Ribeirão Preto 565 192 34.0 302 01/04/2012 01/04/2015 36
 Total 2774 1130 40.7 1497
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To select a population-based sample of controls broadly rep-
resentative of local populations in relation to age, gender, 
and ethnicity, a mixture of random and quota sampling was 
used. Quotas for control recruitment were based on the most 
accurate local demographic data available. Quotas were then 
filled using a variety of recruitment methods, including (1) 
random sampling from lists of all postal addresses (e.g. in 
London); (2) stratified random sampling via GP lists (e.g. 
in London and Cambridge) from randomly selected surger-
ies; and (3) ad hoc approaches (e.g. internet and newspa-
per adverts, leaflets at local stations, shops, and job cent-
ers). In some sites (e.g. London), some groups (e.g. black 
African and black Caribbean) were oversampled to enable 
subsequent sub-group analyses. To deal with this in subse-
quent analyses, weights were generated, based on the most 
accurate local demographic data available, to minimize any 
resulting bias in estimating the prevalence of exposures 
among controls.
Individuals who agreed to take part were screened for 
a history of psychosis. Those who reported previous or 
current treatment for psychosis were excluded. Those who 
responded positively to any question in the screening instru-
ment, indicating a possible psychotic experience, were 
interviewed further with standardised interviews to assess 
symptoms and to establish the presence or otherwise of a 
psychotic disorder. On this basis, no potential controls were 
found to have a past or current psychotic disorder.
Data contents
We collected data on an extensive range of exposures and 
outcomes across multiple domains using previously vali-
dated questionnaires, tasks, and procedures: demographic, 
clinical, social, psychological, cognitive, and biological 
(Table 2). All environmental exposures and cognitive and 
psychological tests were measured using previously vali-
dated questionnaires and tasks.
Genetic risk was assessed both indirectly, using a familial 
liability score for psychosis [28], and directly, using DNA 
extracted from two 9 ml non-fasting venous blood sam-
ples and/or via saliva samples (Oragene). Samples were 
genotyped using custom Illumina HumanCoreExome-24 
BeadChip genotyping arrays containing probes for 570,038 
genetic variants (Illumina Inc., San Diego, CA, USA). 
Genotype data were called using the GenomeStudio pack-
age, transferred into PLINK format for further analysis, and 
underwent quality control based on genotype variants and 
samples.
Quality assurance and control
Prior to and during data collection, annual multi-site meet-
ings were arranged to bring together principal investigators 
and core researchers to ensure that standardised procedures 
were being implemented, to provide training, to discuss 
issues with data collection, and to conduct inter-rater reli-
ability exercises. The study was designed to ensure compara-
ble procedures and methods across settings, with some local 
adaptation to allow for variations in healthcare provision 
and health service contact points. The primary deviation 
from protocol was in the Veneto region, Italy, where data 
were derived from a previous study which used comparable 
methods [29], but had a lower upper-age limit of 54.
Training of researchers who were responsible for admin-
istrating the assessments was performed at the outset and 
throughout the study. This was organised by a technical 
working committee of the overall EU-GEI study (Work 
Package 11). An online resource was made available with 
taped interviews, samples of recordings, and written sum-
maries for staff training purposes. Inter-rater reliability was 
assessed annually. Researchers were required to attain and 
maintain a minimum threshold of correct ratings before 
being allowed to administer the core assessments. Sufficient 
levels of inter-rater reliability for the core measurements, 
ranging from 0.70 to 0.91, were achieved, and are shown 
in Table 3.
Data management
Data were collected on paper and, for some cognitive tasks 
(e.g. the White Noise Task), on laptops and securely stored 
at each of the participating centres, and was entered locally 
using an encrypted web-based system, using commercial 
software (4D) that was adapted specifically for EU-GEI pur-
poses. Data were entered once with field codes restricted to 
logical values where possible, to minimise data entry errors. 
Blood or saliva samples were taken at approved clinical 
research facilities by an experienced researcher and were 
fully anonymized and identified by bar code, and sent to the 
Institute of Psychological Medicine and Clinical Neurology 
at Cardiff University for genotyping. The data resource has 
undergone a rigorous period of validation checks and clean-
ing by a small number of experienced researchers. This has 
involved checks of missing data and corroboration of these 
against the paper files at each of the 17 sites.
Ethical approval
All participants who agreed to take part in the study pro-
vided informed, written consent following full explanation 
of the study. Ethical approval for the study was provided 
by relevant research ethics committees in each of the study 
sites [30].
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Table 2  EU-GEI study battery summary for the case–control study
Instruments Variables/purpose
Clinical and biological OPCRIT  4a [1, 2] Research  diagnosisc
Nottingham Onset  Scalea [3] Onset of psychotic symptoms
Date of first contact with services
Medicated treatment start date for psychosis
Duration of untreated psychosis
Record of clinical diagnosis
Schedule for deficit  syndromea [4] Presence of any deficit syndrome
Community assessment of psychic  experiencesb [5] Assessment of psychopathology in control participants
Structured interview for schizotypy—revisedb [6, 7] Assessment of schizotypy in control participants
Global assessment of functioning  scalesa,b [8] Severity of symptoms
Impairment of function
Family interview for genetic  studiesa, b [9] Family history of psychosis or other mental illness in first 
degree relatives of the proband
Medication  lista, b Past and present medication use
Premorbid Adjustment Scale—shorteneda,b [10, 11] Child and adolescent social adjustment
Child and adolescent academic adjustment
Adolescent sexual adjustment
Blood sample and cheek  swabsa,b DNA
Socio-demographic MRC socio-demographic schedule—modifieda,b [12] Age, gender, and ethnicity
Place of birth (participant and parents)
Age of migration
Social class (participant and parents)
Past and present addresses
Household and living circumstances (past and present)
Educational attainment
Employment status (past and present)
Relationship status (past and present)
Income and poverty status (past and present)
Religion
Environmental exposures Childhood experiences of care and  abusea,b [13, 14] Number of household arrangements
Separation from or death of parents
Other adverse events (taken into care, excluded from 
school, run away from home, physical neglect)
Absence of peer or adult supports
Perceived loneliness
Household discord
Childhood abuse (physical, sexual, emotional)
Amended Bullying  Questionnairea,b [15, 16] Victim of childhood bullying
Childhood Trauma  Questionnairea,b [17] Abuse (physical, sexual, emotional)
Neglect (physical, emotional)
List of threatening  eventsa, b [18, 19] Stressful events and difficulties in the year prior to onset 
(cases), prior to interview (controls)
Social environment assessment  toola,b [20] Subjective rating of participant’s neighbourhood (e.g. trust 
and cooperation)
Major Experiences of Discrimination  Scalea,b [21, 22] Lifetime exposure to discrimination
Cannabis Experience Questionnaire—modifieda,b [23] Detailed use of cannabis (past and present) and other 
recreational drugs
CIDI—tobacco and alcohol  lista,b [24] Present alcohol and tobacco use
Bologna migration  historya,b [25] Migration history
Devaluation of Consumers  Scalea,b [26] Perception of stigma




There were similar proportions from minority ethnic 
groups among consented and non-consented cases (43% 
vs. 40%). However, the proportion of men and the propor-
tions in younger age groups were higher among consented, 
compared with non-consented, cases (men: 62% vs. 57%; 
aged 18–34 years: 69% vs. 60%) (Table 4a). Compared 
with the general population, controls were more likely to 
belong to a minority ethnic group (controls: 28%, popu-
lation at-risk: 23%) and were younger (aged between 18 
and 34 years, controls: 56%, population at-risk: 38%) 
(Table 4b). The greater proportion of controls who were 
from minority ethnic groups  reflects oversampling in 
some sites (e.g. London) to enable subsequent sub-group 
analyses.
Cases were younger than controls {median age of cases 
was 29 years [interquartile range (IQR) 22–37], and con-
trols 33 years old [IQR 26–47]}. Compared with controls, 
a greater proportion of the cases were men (62% vs. 49%), 
migrants (28% vs. 22%), and left school without any quali-
fications (16% versus 6%); a smaller proportion was of 
white ethnicity (63% versus 73%) (see Supplementary 
Table S2).
Discussion
This study was conducted in a diverse range of settings 
across Europe and one setting in Brazil, selected to ensure a 
mix of urban and rural areas with large migrant and minor-
ity ethnic populations. This maximises its applicability to 
and importance for public health initiatives, with potential 
implications for both prevention and intervention, particu-
larly among minority ethnic groups, and in urban areas, and 
in relation to cannabis and other substance use and develop-
mental adversity. Our primary hypotheses centre on examin-
ing variations in incidence and symptoms, environmental 
risk factors, and the interplay between environment and 
genetic factors in the development of psychotic disorders.
Incidence and symptoms
We have already published findings of the overall varia-
tions in incidence of psychoses by site [30]. Our findings 
suggest marked geographical differences in the incidence 
of psychotic disorders, with around an eightfold variation 
among study sites after accounting for age, sex, and minor-
ity ethnic status. At an area level, initial analyses suggest 
that some of this variation may be related to the proportion 
Table 2  (continued)
Instruments Variables/purpose
Cognitive and psychological Brief Core Schema  Scalea,b [27] Attributional bias
Brief Impact of Event  Scalea,b [28, 29] Post-traumatic impact of stressful events
Jumping to conclusions beads  taska,b [30] Probabilistic reasoning bias
White noise  taska, b [31] Attributional bias to random events
Degraded  facesa,b [32] Deficits in facial affect processing





c OPCRIT assessment was based on a semi-structured clinical interview, or review of case notes and other relevant information. OPCRIT has 
been shown to have high inter-rater reliability generally [35, 36], and in our study following training (κ = 0.7)
[1 –34]See Supplementary Appendix A1 for reference list of relevant assessments
Table 3  Inter-rater reliability scores of 115 core researchers
Reliability κ
SIS-R overall 0.79
Positive symptom scale 0.79
Negative symptom scale 0.80
GAF 0.83
OPCRIT 0.70
List of threatening events 0.71
Childhood experiences of care and abuse 0.82
Bullying 0.91
Social class 0.81
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of owner-occupied homes in an area (a tentative proxy for 
social cohesion or socioeconomic deprivation), i.e. areas 
with more owner-occupied homes had, on average, lower 
rates of psychotic disorder. Analyses of variations in inci-
dence by ethnic group are ongoing. Analyses of symptom 
data on incident cases, collated using the OPCRIT, have 
examined the validity of a transdiagnostic dimensional 
structure of psychopathology and, in doing so, have chal-
lenged the common binary categorisation of psychoses into 
non-affective and affective disorders [31]. Our findings sug-
gest that a bifactor model of psychopathology, comprising 
one general factor and five dimensions (positive, negative, 
manic, disorganised, and depressive symptoms), best rep-
resents the structure of symptoms among those with a psy-
chotic disorder. We further found, compared with majority 
populations, cases in minority ethnic groups scored higher 
on the positive psychotic symptom dimension; and, com-
pared with rural areas, cases in urban areas scored higher 
on the general symptom dimension.
Environmental risk
The initial focus of analyses of our case–control data 
resource is the associations and population impact of 
Table 4  Representativeness of (a) the consented case sample compared with the incidence sample, and (b) the control sample compared with the 
population-at-risk
Missing data on
a 6 incidence cases
b 4 incidence cases
c 47 incidence cases (42 of whom were from Puy-de-Dôme), and 3 assessed cases
d 2 controls
e 5 controls
f This does not include Paris, as no controls were recruited here
Incidence cases Consented cases χ2 p value
n % n %
Agea
 18–24 808 29.2 415 36.7 35.24 < 0.01
 25–34 868 31.4 365 32.3
 35–44 558 20.2 204 18.1
 45–54 382 13.8 104 9.2
 55–64 152 5.5 42 3.7
Sexb
 Male 1578 56.9 697 61.6 7.34 < 0.01
 Female 1192 43.1 433 38.4
Ethnic minority  statusc
 Majority 1639 60.2 648 57.5 2.24 0.13
 Minority 1088 39.8 479 42.5
Population at-risk Controlsf χ2 p value
n % n %
Aged
 18–24 1,828,075 14.1 322 21.5 210.70 < 0.01
 25–34 3,057,640 23.6 512 34.3
 35–44 3,058,837 23.7 232 15.5
 45–54 2,856,614 21.9 254 17.0
 55–64 2,152,499 16.6 175 11.7
Sex
 Male 6,337,783 49.5 706 47.2 3.29 0.07
 Female 6,464,653 50.5 791 52.8
Ethnic minority  statuse
 Majority 9,881,660 77.2 1084 72.1 17.54 < 0.01
 Minority 2,917,823 22.8 408 27.9
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putative environmental risk factors, including childhood 
adversity and abuse, adult adversity, discrimination, and 
cannabis use. In analyses of cannabis use data, for example, 
we found that, compared with those who did not use canna-
bis, the odds of psychosis were (1) around three times higher 
among those who used cannabis daily; (2) around two times 
higher among those who spent more than 20 Euros a week 
on cannabis; and (3) around 50% higher among those who 
used cannabis high in THC [32]. In addition, we found vari-
ations in population attributable fractions for daily canna-
bis use on psychosis [32], with population attributable frac-
tions (i.e. the proportion of psychosis, assuming causality, 
attributable to daily use) ranging from 1 (in Puy-de-Dôme, 
France) to 44% (in Amsterdam). Similar analyses examining 
childhood and adult adversity are ongoing, focusing on type, 
severity, and age of exposure (Morgan et al., in preparation).
These analyses will be further extended to examine envi-
ronment–environment and gene–environment interactions 
and to more clearly elucidate the pathogenic processes 
underpinning observed variations in incidence across study 
sites [30] and high rates of psychotic disorders in urban areas 
[7, 8], and in migrant and minority ethnic groups [9, 10].
Strengths and weaknesses
To our knowledge, this is the most extensive multi-site inci-
dence and case–control study of first-episode psychosis ever 
conducted, with comprehensive data on a variety of envi-
ronmental, psychological, and genetic risk factors. The pri-
mary strength of the EU-GEI study is its potential to provide 
ground-breaking and important information about the devel-
opment of psychoses, by investigating the complex interrela-
tionships between candidate environmental, psychological, 
and biological (genetic) factors and psychotic disorders, 
including the mechanisms through which they increase risk. 
In addition, given that our study was carried out in major 
urban and rural sites with heterogeneous populations sug-
gests that our external validity may extend to other centres 
with similar population profiles. The combined incidence 
and case–control methodology allows for precise identifi-
cation of, and ability to account for, any potential selec-
tion biases amongst the recruited and assessed cases. The 
richness of the exposure information available will allow 
for more nuanced analyses and a more fine-grained under-
standing of their impact on psychotic disorder than has been 
possible to date. Importantly, the inclusion of only cases 
with a first episode of psychosis (rather than individuals with 
long-standing disorder) allows inferences to be made about 
causal connections and processes.
The primary limitation of these data resource relates 
to case identification. As in all previous studies, we relied 
on first contact with mental health services as a proxy for 
first onset. While it is likely most individuals who develop 
a psychotic disorder do present to services, at least in sites 
with well-developed public health systems, some who do 
not present will be missed and this may introduce selection 
biases. Any rate estimates should, therefore, be considered as 
treated incidence. Further, variations in referral procedures 
of patients with psychosis from primary to secondary mental 
health care settings and in the organization of secondary 
mental health care services across catchment areas may have 
influenced the identification of cases, and may explain some 
of the variation in estimates of incidence across study sites 
and countries. For example, unlike in other settings, patients 
in Madrid are not constrained to using mental health services 
in their residential catchment areas [33]. However, as high-
lighted by Jongsma et al. [30], the divergences in service 
provision and cultural context are unlikely to fully explain 
the eightfold variation in incidence across sites.
There are also several limitations that are inherent to 
case–control designs. First, while substantial efforts were 
made at the outset to reduce the potential biases in the iden-
tification of cases (e.g. recruitment of participants from a 
number of sources using a variety of methods, including 
inpatient wards and community teams) and controls (e.g. 
use of mixture of random and quota sampling), we were not 
entirely successful; our cases are not fully representative of 
the sample identified in the incidence study, and our controls 
not of the population-at-risk. For example, reliance in some 
sites on recruitment of controls through ad hoc methods, 
such as newspaper advertisements, may have biased sam-
ples. Interpretations of estimated effects (odds ratios) should 
be considered with this in mind.
Second, there is the potential for both recall and observer 
bias. To minimise these, and validate environmental expo-
sures, several steps were taken. For core environmental 
exposures (e.g. childhood adversity and cannabis use), we 
used extensive, well-validated measures, that drew on life 
course methods to anchor memories and improve recall. All 
researchers administering these assessments went through 
intensive training, with regular top-ups. Further, where 
possible, we drew on corroborative sources of information 
in the assessment of exposure to childhood and adulthood 
adversity [e.g. clinical records, interviews with siblings of a 
subsample of cases (n = 272)].
Third, measurement of exposure occurred after onset of 
disorder, making causal inferences problematic. To establish 
the temporal ordering of exposure and outcome, we carefully 
established the date of onset of disorder and, for measures 
of exposures in childhood and adulthood, ensured that all 
assessments related to the period pre-onset.
Finally, given the large battery of tests and interviews 
conducted with our participants, data were missing for some 
assessments, particularly towards the end of the study bat-
tery. Where appropriate, a standardised procedure for multi-
ple imputation will be used to minimise the loss of precision 
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or selection biases which may otherwise be introduced in 
complete case analyses.
Data resource access
The EU-GEI WP2 principal investigators (contact: craig.
morgan@kcl.ac.uk) welcome formal requests for access to 
the data, biological samples, and/or collaborative projects. 
Researchers will be required to complete an EU-GEI WP2 
data interest form to state their intended hypotheses and 
analysis plan, which will be reviewed by the PIs to determine 
whether the proposal can be addressed by this data resource, 
does not duplicate on-going or completed analyses with this 
dataset, and lies within the scope of current ethical approv-
als. More information about the study can be found on the 
study website (https ://www.eu-gei.eu/).
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